Building the digital foundations that can turn artificial intelligence from an experiment into a scalable, compliant business capability
Pharmaceutical and MedTech companies are being asked to move faster than ever while operating within increasingly demanding regulatory environments. Innovation, compliance and efficiency must progress together, yet achieving that balance requires more than the introduction of new technology. It depends on how effectively products, processes, data and systems are connected across the organisation.
For engineering and consulting specialist Helbling, this intersection between technology and regulated industry has become increasingly important. With more than 30 years of experience in the Life Sciences sector, the company has contributed to the development of more than 200 medical devices, instruments, laboratory systems and healthcare solutions, spanning hardware, software, electronics, automation, manufacturing systems, quality management and regulatory requirements.
The difficulty is rarely the AI model itself. Success depends on the data, processes, controls and regulatory framework surrounding it.
That multidisciplinary experience now extends into digital transformation, where product development, manufacturing, quality and regulatory processes are increasingly being connected through a common digital infrastructure.
It is within this environment that Agentic AI is beginning to attract significant attention. Unlike conventional AI applications that primarily analyse information or respond to individual prompts, Agentic systems can plan and carry out tasks with a degree of autonomy. For Life Sciences companies, the potential is considerable, although moving from a successful pilot to a dependable enterprise capability remains one of the industry’s biggest challenges.
The difficulty is rarely the AI model itself. Instead, success depends on the quality of the underlying data, the integration of systems and processes, the controls surrounding the technology and, critically, whether the solution has been designed around the realities of a regulated environment.
Building a Closed Loop
A scalable AI environment requires a reliable digital foundation.
Helbling approaches this through Closed Loop Manufacturing, or CLM, which connects key systems including Product Lifecycle Management, Enterprise Resource Planning and Manufacturing Execution Systems. The objective is to maintain consistent product and process definitions, production information and quality data across the full lifecycle, creating the traceability required for both operational efficiency and regulatory compliance.
Central to this approach is the Bill of Process, which forms part of the digital representation of the manufacturing process. It brings together manufacturing and inspection steps, machine parameters, recipes and specifications, while also defining the documentation required throughout production.
Where records such as Master Production Records and Master Batch Records are digital, organisations can automate parts of the compliance process and continuously compare production performance against defined parameters.
This becomes particularly important when AI is introduced.
Life Sciences organisations generate significant volumes of regulatory and quality documentation, including Design History Files, Device Master Records, Device History Records, batch records, change controls and CAPA documentation. Artificial intelligence can potentially analyse these documents, identify inconsistencies and monitor compliance, but its usefulness depends entirely on whether the information it is working with is structured, connected and verifiable.
Without that foundation, an AI agent may simply be interpreting fragmented documents. With it, the technology can operate within a traceable and validated digital environment.
Data Is Only the Starting Point
Most organisations already recognise that the effectiveness of AI depends heavily on the quality of the data behind it. In regulated industries, incomplete or inconsistent information is particularly problematic because the resulting decisions must be capable of being verified and audited.
However, creating a strong data foundation is only part of the challenge.
The greatest value from Agentic AI is likely to emerge when systems can operate across organisational boundaries, drawing information from PLM, ERP, MES, laboratory and quality systems before interpreting that information and taking appropriate action.
Achieving this requires more than simply connecting databases. Organisations must establish integration and control layers that define identities, permissions, data lineage and evidence, while ensuring that information subject to GxP requirements is properly qualified and separated from less regulated workloads.
Security also becomes more important as AI systems gain the ability to initiate actions rather than simply generate recommendations. An incorrect response is one thing; an autonomous system triggering an inappropriate operational action is another.
Permission controls, auditability and governance therefore become fundamental parts of the architecture, alongside requirements surrounding data sovereignty and the handling of sensitive product, patient and manufacturing information.
Rethinking Processes Before Automating Them
One reason AI initiatives struggle to progress beyond pilot projects is that organisations often apply new technology to existing processes without first questioning whether those processes remain appropriate.
Automating an inefficient workflow may make it faster, but it does not necessarily make it better.
A more effective approach begins by defining the outcome a process needs to achieve before considering how artificial intelligence might support it. The workflow can then be redesigned around collaboration between people and technology rather than simply replacing individual tasks.
Helbling breaks these processes into smaller decision units, examining what information is required at each stage and whether the decision should sit with a human expert or an automated system.
This also helps prevent what the company describes as “context pollution”, where an AI system is given more information than it needs and its ability to make reliable decisions is reduced.
The level of autonomy can vary according to risk, but accountability remains with human specialists. Those experts establish thresholds, quality controls and escalation criteria so that intervention takes place when the level of uncertainty or operational risk increases.
In highly regulated environments, this process design can be more demanding than the technical implementation itself. Understanding what a workflow needs to achieve from a compliance perspective, and then redesigning it around emerging AI capabilities, requires both industry expertise and a detailed understanding of the underlying technology.
Two applications developed by Helbling demonstrate how this approach could translate into practical use.
AI-Powered Regulatory Compliance
Quality Management Systems within the Life Sciences industry can contain thousands of Standard Operating Procedures, work instructions, specifications and validation documents spread across multiple products, sites and legal entities.
As organisations expand, those systems often become increasingly fragmented. Documents are duplicated, regulatory requirements may be interpreted differently across locations and maintaining connections between related records becomes more difficult.
Regulatory changes can therefore trigger substantial manual review work while still leaving organisations exposed to potential compliance gaps.
Helbling’s Regulatory Compliance Navigator is designed to analyse quality documentation continuously, comparing SOPs, work instructions and quality records against requirements including FDA regulations, the European Medical Device Regulation and organisation-specific standards.
The system can identify inconsistencies, missing references and conflicting instructions while also highlighting opportunities to harmonise documentation between sites and products.
It can then recommend updates and assess the potential downstream consequences of those changes, moving compliance away from periodic manual review towards a more continuously monitored approach.
For large international organisations, the potential advantage is not simply reducing administrative effort, but creating a more consistent and scalable Quality Management System.
The future of Agentic AI will be shaped by the organisations willing to rethink the processes underneath the technology.
Improving Quality Control
Quality Control presents a different challenge.
Laboratory capacity, specialist analysts and testing equipment are finite resources, yet manufacturers must manage growing volumes of batches, samples and release activities.
Traditional planning often relies on fixed rules and manual prioritisation, which may not account for changes elsewhere in the manufacturing or supply chain. Delays in releasing a critical batch can therefore create problems that extend far beyond the laboratory, affecting production schedules, customer deliveries and inventory.
Helbling’s Quality Control Navigator combines information from production orders, inventory levels, downstream demand, available laboratory resources, equipment capacity, alternative testing methods, Non-Conformance Management Reports and partial batch-release strategies.
Using this information, the system can generate testing and release schedules and continuously adjust priorities as production conditions change.
The objective is to ensure that the most important batches are tested and released at the appropriate time while making more effective use of available quality-control resources. Helbling states that this approach can reduce costs by up to 30 per cent while maintaining the flow of material through the manufacturing network.
From Experimentation to Adoption
The future of Agentic AI in Life Sciences is unlikely to be determined by which organisations run the greatest number of pilot projects.
The more important distinction will be between companies that treat AI as an additional technology layer and those willing to examine the processes, systems and governance structures underneath it.
For regulated organisations, traceability, accountability and trust will ultimately determine whether AI moves beyond experimentation.
If the reasoning behind an automated decision cannot be understood, verified or challenged, users are unlikely to rely on it regardless of how sophisticated the underlying technology may be. For that reason, transparency and governance must be designed into both the process and the architecture from the beginning.
Helbling’s work across product development, digitalisation and regulated manufacturing places the company within this broader transition. The technology may be evolving rapidly, but the challenge facing the Life Sciences industry remains much more fundamental: creating the systems, processes and trust required to turn artificial intelligence into something that can deliver measurable value at scale.